Undisclosed bispecific antibody / Rondo Therap - LARVOL DELTA

Potency-optimized CD28-activating bispecific antibody for the targeted treatment of Nectin-4 positive cancers. (PubMed, J Immunother Cancer) - "Our study reports the first CD28 bsAb targeting Nectin-4 and highlights the potential of CD28 × Nectin-4 bsAbs as a new immunotherapeutic modality. The findings support the clinical development of RNDO-564 in patients with locally advanced and metastatic UC and other Nectin-4 positive malignancies."

IO biomarker • Journal • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • Urothelial Cancer • NECTIN4

A novel CD28 x Nectin-4 costimulatory bispecific antibody for advanced bladder cancer. (ASCO-GU 2025) - "Background: Effective T-cell activation is driven by multiple signals. RNDO-564 has a high affinity Nectin-4 binding arm and an affinity-tuned CD28 arm optimized for activity in metastatic bladder cancer. A phase 1 study is planned to evaluate the safety, tolerability, PK/PD, and clinical activity of RNDO-564 alone and in combination with CPI in mUC."

Metastases • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • Urothelial Cancer • NECTIN4

A novel CD28 x Nectin-4 costimulatory bispecific antibody targeting metastatic bladder cancer (SITC 2024) - "As of 2023, standard of care for metastatic urothelial carcinoma(mUC) in the first line setting is Padcev in combination with checkpoint inhibitors (CPI). Conclusions RNDO-564 has favorable functional and developability characteristics and is being developed to enter a Phase I clinical trial in 2025 targeting mUC. Ethics Approval The study was approved and designated an IACUC number ASP #: 980701.Download figure Open in new tab Download powerpoint Abstract 939 Figure 1 Schematic illustrating RNDO-564"

Metastases • Bladder Cancer • Genito-urinary Cancer • Hematological Malignancies • Oncology • Solid Tumor • Urothelial Cancer • NECTIN4